Getinge AB shares rallied over 10% after second-quarter 2026 results exceeded analyst expectations.
The medical technology firm reported organic net sales growth of 4.6%. Adjusted EBITA margin reached 17.6%.
A tariff refund and improved operational performance supported the margin expansion. Organic order intake increased by 6.2%.
The results indicate progress toward the company's mid-term profitability targets.